



# Proteomics International

LABORATORIES LTD

ASX/Media Release

24 October 2018

ASX code: PIQ

## PromarkerD test for diabetic kidney disease to enter Europe as Proteomics wins Export Award

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), which has pioneered the world-leading PromarkerD predictive diagnostic test for diabetic kidney disease already licensed in the USA and Mexico, announces a further licence deal for the Spanish market with Patia Europe.

Proteomics International also announces it has received recognition for its export success by winning the WA Export Award in the Health and Biotechnology category at the 30th Western Australia Industry & Export Awards, held last Thursday.

- **PromarkerD predictive test for diabetic kidney disease licensed to Patia Europe for Spanish market where 3.6 million adults have diabetes**
- **Proteomics International wins WA Export Award in the Health and Biotechnology category on back of innovative products and export derived revenue doubling to \$795,000 in FY18**
- **Proteomics International continues to advance the commercialisation of PromarkerD, and the development of new diagnostic products and analytical services for its expanding global market base**

The PromarkerD predictive test for diabetic kidney disease can detect the onset of disease up to four years before clinical symptoms appear. Existing tests are only able to detect chronic kidney disease after it is present. Currently there are 3.6 million adults with diabetes in Spain, where, like the rest of Europe, the incidence of diabetes is increasing rapidly.

The exclusive licence agreement with Patia Europe for Spain is for two years and Proteomics International will receive a royalty on each test sold. The licence will see Patia Europe commercialise the PromarkerD mass spectrometry "Laboratory Developed Test" (LDT). The LDT permits fast adoption of a new test in advanced markets. First sales are anticipated to be within six months, and as for any novel test, market penetration and sales cannot be predicted accurately.

"PromarkerD is a break-through test that allows us to pre-empt diabetic kidney disease, one of the most costly complications of diabetes," said Laureano Simon, PhD, Chief Executive Officer of Patia Europe. "This predictive test will let us intervene early and prescribe treatments to prevent the disease, and help reverse the growing impact of diabetes on public health in Spain."

The new deal builds upon Proteomics International recently announced licences for PromarkerD in the USA with PHDx Inc and in Mexico with Patia Biopharma [ASX: 21 June]. The world-first test for predicting the onset of diabetic kidney disease is due to launch in the USA within weeks, and in Mexico in the New Year.

Proteomics International's export award reflected the company's doubling of export derived

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

revenue to \$795,000 for the 2018 financial year, coupled with growth in long term markets such as India, and expansion into new markets with first sales to China and the Netherlands.

Proteomics International Managing Director Dr Richard Lipscombe said the expansion of PromarkerD into global markets and the launch of new analytical services served to highlight Proteomics International's export achievements and strategy for company growth. "We look forward to announcing further opportunities for commercialising PromarkerD and developments in our Promarker™ diagnostics pipeline in the coming months", he said.

ENDS

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: enquiries@proteomicsinternational.com

Susan Fitzpatrick-Napier  
[Public Relations & Media Contact]  
Digital Mantra Group  
T: +61 2 8218 2144  
E: team@dmgpr.com

**About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

PromarkerD is a predictive diagnostic test for diabetic kidney disease. In clinical studies presented in 2017 at the American Diabetes Association Annual Scientific Sessions [ASX: 10 June 2017] and published in the prestigious journal Diabetes Care [ASX: 6 September 2017], PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years.

PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its report titled Biomarkers Enabling Diabetes and Obesity Management [ASX: 27 March 2017]. PromarkerD has received patent protection in several major jurisdictions including the USA, China, Europe, and Japan, with others pending.

Further information is available through the PromarkerD web portal.

**About Patia Europe ([www.patiadiabetes.com/en](http://www.patiadiabetes.com/en))**

Patia Europe is established in Spain as a subsidiary company of Patia Biopharma Mexico. Patia is a public health company that integrates genomic, proteomic and metabolomic tools, with digital applications, to prevent and manage type 2 diabetes and gestational diabetes.

Patia is supported by billionaire Carlos Slim and the SIGMA project, carried out at the Broad Institute of Harvard University and MIT, located in Cambridge, Massachusetts, US.

The SIGMA project, funded with US\$176 million by the Carlos Slim Foundation, set out to identify genetic risk factors for diabetes. Analysis has discovered new genetic variations that are associated with type 2 diabetes, and Patia is now translating this knowledge into clinical devices to improve treatment of the disease.

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the company's world-leading test for diabetic kidney disease, PromarkerD, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests, and offset the cash burn from R&D and product development through provision of specialist analytical services.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)